echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Brit J Cancer: The prognostic value of NLR in patients with advanced pulmonary large cell neuroendocrine cancer and its relationship to the micro-environment of immuno-related tumors

    Brit J Cancer: The prognostic value of NLR in patients with advanced pulmonary large cell neuroendocrine cancer and its relationship to the micro-environment of immuno-related tumors

    • Last Update: 2020-12-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The prognostic value of neogenitive granulocyte-to-lymphocyte ratio (NLR) for patients with pulmonary large cell neuroendocrine cancer (LCNEC) is not yet clear.
    , researchers conducted a retrospective study to assess the relationship between pre-treatment NLR and clinical outcomes in patients with advanced LCNEC, as well as the effects of immuno-related tumor microeconients (TME), in a recent study published in British Journal of Cancer, an authoritative journal in the field of oncology.
    retrospective study included 63 patients with advanced LCNEC who received chemotherapy.
    researchers collected clinical data from subjects and investigated TME status (CD4, CD8, CD20, and FOXP3).
    survival of patients with low NLR (-lt;5) was significantly higher than that of patients with high NLR (≥5) (14.9 vs. 5.2 months; p.lt;0.001).
    multi-factor analysis shows that higher NLRs can predict poor prognostics (HR is 3.43; 95% CI is 1.73-6.79; p.lt;0.001).
    NLR was negatively corred with tumor and substring CD8-positive tumor-soaked lymphocytes (tumors: r=0.648, p=0.005, substitly: r=-0.490, p=0.046).
    can be seen that high NLR is associated with poor prognostics in patients with advanced LCNEC.
    the results of this study show that NLR can reflect TME at least partially, suggesting that NLR not only acts as a clinical prognosmation indicator, but also serves as an indicator of tumor immune status.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.